Mirum Pharmaceuticals, Inc. announced preliminary and unaudited full-year 2024 net product sales of approximately $336 million. This figure exceeded the upper end of the company's previous guidance range, indicating robust commercial performance.
For the full year 2025, Mirum provided expected global net product sales guidance of $420 million to $435 million. This forward-looking statement reflects confidence in continued demand for its approved products and pipeline advancements.
The company also provided updates on its pipeline, stating that the VISTAS study of volixibat in primary sclerosing cholangitis is expected to complete enrollment in the second half of 2025, with topline data anticipated in 2026. Additionally, Mirum noted the NDA submission for chenodiol and the in-licensing of MRM-3379 for Fragile X syndrome, further diversifying its rare disease efforts.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.